Abbott announced today that the U.S. Food and Drug Administration has approved the company’s Absorb bioresorbable heart stent, making the first-of-its-kind medical device commercially available to treat people with coronary artery disease in the United States.
Absorb is the only fully dissolving stent approved for the treatment of coronary artery disease, which affects 15 million people in the United States and remains a leading cause of death worldwide, despite decades of therapeutic advances. While stents are traditionally made of metal, Abbott’s Absorb stent is made of a naturally dissolving material, similar to dissolving sutures. Absorb disappears completely in approximately three years, after it has done its job of keeping a clogged artery open and promoting healing of the treated artery segment. By contrast, metal stents are permanent implants that restrict vessel motion for the life of the person treated.
To view the multimedia release go to:
http://www.multivu.com/players/English/7826651-abbott-fda-approval-stent/
The Perelman School of Medicine at the University of Pennsylvania and the March of Dimes Foundation announce the launch of a new $10 million Prematurity Research Center here.
The March of Dimes will invest $10 million during the next five years to create a transdisciplinary center conducting team-based research, led by physicians and researchers at the Hospital of the University of Pennsylvania and The Children’s Hospital of Philadelphia, to discover the unknown causes of preterm birth and develop new strategies to prevent it. This March of Dimes Prematurity Research Center at the University of Pennsylvania is part of a “medical Manhattan Project” of five such centers in the United States created by the foundation since 2011.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/65164-march-of-dimes-march-for-babies-2014/
Oura Health, the Finnish health technology company behind the Oura ring, has moved its total private funding to 12.5M€ after the closure of a round led by US-based Bold Capital Partners and Finland’s Tesi. The funding will be used to scale US market operations and push the Oura platform forward.
The Oura ring and app guides wearers towards better sleep, recovery and readiness to perform by analyzing the body’s sleep, activity levels, daily rhythms and physiological responses.
To view the multimedia release go to:
https://www.multivu.com/players/uk/8362451-oura-health-strengthens-position-us-market/
The Leukemia & Lymphoma Society (LLS) today announced it has committed $28.6 million in new research investment to advance the most promising blood cancer science at leading academic and medical institutions around the world, including Dana-Farber Cancer Institute, Weill Cornell Medical College and MD Anderson Cancer Center. As LLS leads the charge to find cures for cancer patients, this new funding, along with ongoing investment in LLS’s aggressive research agenda, brings LLS’s total commitment to blood cancer research to more than $1 billion. The investment has led to the development of nearly every therapy currently used to treat the blood cancers.
Along with these new research grants, LLS remains committed to collaborating with biotechnology companies through its innovative Therapy Acceleration Program® (TAP), a model pioneered by LLS in the cancer arena in recognition that traditional research approaches weren’t yielding treatments and cures fast enough for patients. LLS commits approximately $13 million a year to its TAP initiatives. As part of the 24 current such collaborations, LLS recently initiated new investments with Kite Pharma and OncoPep.
To view the multimedia release go to:
http://www.multivu.com/players/English/7554852-lls-cancer-research-funding/
LivaNova PLC (NASDAQ:LIVN; LSE: LIVN) (“LivaNova” or the “Company”), a market-leading medical technology and innovation company, today recognizes that more than one million people in the United States with drug-resistant epilepsy continue to be treated unsuccessfully with drugs, despite the proven effectiveness of non-drug treatment options. LivaNova’s VNS Therapy®, for example, is a medical device treatment specifically designed for people with drug-resistant epilepsy that is already used by more than 85,000 people around the world.
One in three people with epilepsy has the type that is not well controlled with drugs, called drug-resistant epilepsy. For those people, prescribing more medicine is usually not the most effective option. In fact, research shows that if you haven’t found seizure freedom after your first two drugs, there is a 95 percent chance that no drug or combination of drugs will result in seizure freedom.
“Despite what we know about drug-resistant epilepsy, the majority of people affected by this condition will continue to be prescribed additional medications instead of being evaluated for surgery or seen in a specialized epilepsy facility,” said Jason Richey, president of LivaNova’s U.S. Region and general manager of the Neuromodulation Business Franchise. “This treatment gap means over one million individuals in the U.S. with undertreated epilepsy remain at risk for dangerous side effects of continued seizures, including injury, depression, memory issues and death.”
To view the multimedia release go to:
http://www.multivu.com/players/English/7966451-livanova-vns-therapy-epilepsy/
In this video, we'll teach you how to optimize your SEO.
If you're a doctor looking to improve your website traffic and rank in search, this video is for you! By following the tips in this video, you'll be able to improve your website's visibility and reach new patients who need your help!
Duchesnay USA launched a new online video series today about pregnancy health and morning sickness, which many don’t know is a medical condition called Nausea and Vomiting of Pregnancy (NVP). The series, entitled Navigating Morning Sickness, premiered with three videos about pregnancy nutrition, medication safety and the potential impact of NVP on a pregnant woman’s life. Additional new videos will be released throughout November and December.
To view Multimedia News Release, go to http://www.multivu.com/mnr/64373-duchesnay-usa-online-video-series-pregnancy-morning-sickness
Invuity, Inc. (NASDAQ:IVTY), an advanced medical technology company, announced today the launch of its Hidden ScarTM Surgery program designed to certify surgeons and establish Centers of Excellence at major cancer centers and hospitals across the country. This innovative program will train surgeons on advanced minimally invasive and minimal access surgical approaches that deliver optimal clinical and aesthetic outcomes for patients. As part of the company’s broader women’s health initiative, Invuity is hosting a Hidden Scar Breast Cancer Surgery training course in advance of the American College of Surgeons (ACS) Clinical Congress.
Invuity aims to transform the surgical treatment of breast cancer with this advanced surgical approach for nipple sparing mastectomies and lumpectomies (breast conserving surgery). Hidden Scar Breast Cancer Surgery expands surgical options for patients, offering superior cosmetic outcomes that can improve their psychological and emotional recovery and enhance quality of life after surgery.1
With growing demand for less invasive alternatives to breast cancer surgery, surgeons need to operate through smaller incisions with limited fields of vision. Invuity’s illumination technology allows surgeons to access and visualize the entire breast cavity through discrete incision locations, enabling surgeons to safely and effectively treat breast cancer while preserving the natural shape of the breast and thereby minimizing and hiding the scars.
To view the multimedia release go to:
http://www.multivu.com/players/English/7644051-invuity-hidden-scar-breast-cancer-surgery-program/
Every spring, allergies take control of the lives of millions of Americans, affecting their work, their family time and even how well they sleep at night. Something else affects those millions of allergy sufferers, according to a new survey: big misconceptions about allergies that may keep people from getting needed relief.
To help put those misconceptions about allergies to rest, Sanofi is teaming up with science educator and television personality Adam Savage, along with allergist Dr. Neeta Ogden, to dispel them with credible information. The goal: help the 50 million allergy sufferers in America get the facts they need to understand and treat their allergies and take back control of their lives.
To view the multimedia release go to:
https://www.multivu.com/players/English/8255452-sanofi-allergy-misconceptions-facts-adam-savage/
Chiasma, Inc., a U.S. privately–held biopharma company developing octreotide capsules for the orphan condition acromegaly, today announced two new studies presented at the 97th Endocrine Society (ENDO) Annual Meeting in San Diego, Calif. The studies provide additional data from Chiasma’s Phase III trial and new findings on the patient burden of current injection therapies.
“We now have data to help clinicians determine whether octreotide capsules, if approved, are likely to help their patient with acromegaly maintain response,” said Shlomo Melmed, M.D., senior vice president and dean, Cedars–Sinai Medical Center, Los Angeles and global study principal investigator. “Furthermore, the Phase III results show the safety and efficacy of octreotide capsules can be reliably determined within 12 weeks of initiating therapy.”
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7436451-endo-chiasma-clinical-data/
http://www.lossweightsolutions.co.education
Healthy weight loss solutions - video testimonial healthy weight loss solutions medical spa.
Discover how to get motivated to be healthy by tapping into to your own power Next article Paleo, Gluten Free healthy weight loss solutions hobbs nm and Dairy healthy weight loss solutions hobbs nm Free Product Guide Healthy weight loss solutions fort wayne indiana Find this Pin and more on ilriecen by geri5039
|Loss Solutions Reviews Let's look at the 6 reasons why you are not losing weight
Here at healthy weight loss solutions we are challenging you to do the 30 day squat challenge with us.
how to get motivated to be healthy , how to get motivated to be healthy Start a Healthy Lifestyle in 2018.
Get Healthy Weight Loss Solutions phone number in Rigby, Weight Control Services, Healthy Weight Loss Solutions Reviews.
Healthy weight loss solutions reviews Motivation : Healthy Lunches About Fitness, Health And Body : - Fitness-fitnessmag.
If fat loss is your goal healthy weight loss solutions medical spa,How Eating Right And The Right Exercise Will Better Your Health.
Healthy Weight Loss Solutions Medical Spa *this video from YouTube has been aggregated from our Healthy Eating aggregator.
Healthy weight loss solutions cost,We Bought This Ebook And Used It.
Now, that you know of the common mistakes, let's move on to how to stay motivated for weight loss… Leave a comment below if you enjoyed this article on how to stay motivated to lose weight in 7 simple ways or have any questions.
The main problem people face when wondering how to stay motivated to lose weight is that motivation wears off, and temptation will always exist.
How To » Health & Fitness » Exercise & Nutrition » Weight Management » How To Stay Motivated to Lose Weight.
How to stay motivated to lose weight is something stressing many people.
If you really want to lose weight in a healthy way there’s no way to escape from regular exercise and activity.
Big fat weight loss lie (weight loss vs healthy weight loss).
Today, Brother International Corporation, the leader in laser printing in the small office, home office market, announced its newest line of monochrome laser printers and all-in-ones. From work-from-home-warriors and small-office-heroes to trusted school administrators and busy medical practices, Brother has a proven track record of providing the most reliable printer solutions on the market, and today the best got even better.
The new lineup includes five printers and four all-in-ones to address the evolving needs of the busy home or small office, including the first Brother XL Extended Print laser models that include up to two years of toner in the box. Printers in the new lineup offer fastest-in-class print speeds, high-quality prints, and superb reliability, all while keeping budget in mind.
To view the multimedia release go to:
https://www.multivu.com/players/English/8253851-brother-monochrome-laser-printers-all-in-one/
